Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Collategene Achieves Primary Endpoint in PIII Trial: AnGes MG
May 17, 2010
- PMDA Should Continue, Even Expand Its Activities: Screening by GRU
May 17, 2010
- Asahi Kasei's AT-877 Fails to Meet Primary Endpoint in PIII
May 17, 2010
- PMDA to Relax Working Regulations for Former Company Employees
May 17, 2010
- Hisamitsu's HKT-500 Fails to Meet Primary Endpoint in PIII
May 17, 2010
- Five NIBIO Projects Screened by GRU
May 17, 2010
- NIBIO Identifies Protein Related to Colon, Esophageal Cancer
May 17, 2010
- BI Expects 1st Approval for Dabigatran for SPAF in Late 2010
May 17, 2010
- Korosho to Ask for Development of 109 Drugs/Indications
May 17, 2010
- Lixisenatide Significantly Reduces HbA1c: sanofi-aventis
May 17, 2010
- 68% of Public “Don't Know About HPV” Survey
May 17, 2010
- WG to Discuss Regulatory Requirements for Regenerative Medicine
May 17, 2010
- Merck Serono Begins Infertility Treatment Education Program
May 17, 2010
- Exforge to Compete with Takeda's Unisia: Mr Anderson of Novartis
May 17, 2010
- GRU to Call For Lifting on Ban on Supply of Information on Unapproved Drugs
May 17, 2010
- New JMA Leadership to Follow Former Leadership's Policies
May 17, 2010
- Janssen: Sales Up 2.7% to ¥80.5 Bil.
May 17, 2010
- Takeda Applies for Successor of Blopress in the US
May 17, 2010
- Good Control of Nocturnal Respiratory Symptoms Important in Children: Prof. Mochizuki
May 17, 2010
- Torii to Boost Sales to ¥50 Bil. by FY2012
May 17, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…